Welcome to LookChem.com Sign In|Join Free
  • or
Pyrazinamine, 6-chloro-N-[(1S)-1-phenylethyl]- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

445264-59-5

Post Buying Request

445264-59-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

445264-59-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 445264-59-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,5,2,6 and 4 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 445264-59:
(8*4)+(7*4)+(6*5)+(5*2)+(4*6)+(3*4)+(2*5)+(1*9)=155
155 % 10 = 5
So 445264-59-5 is a valid CAS Registry Number.

445264-59-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-chloro-N-[(1S)-1-phenylethyl]pyrazin-2-amine

1.2 Other means of identification

Product number -
Other names Pyrazinamine,6-chloro-N-[(1S)-1-phenylethyl]

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:445264-59-5 SDS

445264-59-5Relevant academic research and scientific papers

IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS

-

Page/Page column 125, (2011/07/09)

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PROTEIN KINASE INHIBITORS

-

Page 34, (2008/06/13)

A compound of general formula (I) or pharmaceutically acceptable salts, hydrates, solvates, crystal forms of diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of Formula (I) is also described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 445264-59-5